Kopp Investment Advisors LLC lessened its holdings in shares of Intersect ENT Inc (NASDAQ:XENT) by 10.0% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 201,943 shares of the medical equipment provider’s stock after selling 22,429 shares during the quarter. Intersect ENT accounts for 6.6% of Kopp Investment Advisors LLC’s portfolio, making the stock its largest position. Kopp Investment Advisors LLC owned 0.69% of Intersect ENT worth $6,543,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also modified their holdings of the company. Oppenheimer Asset Management Inc. acquired a new stake in Intersect ENT during the 3rd quarter valued at approximately $117,000. Great West Life Assurance Co. Can acquired a new stake in Intersect ENT during the 3rd quarter valued at approximately $116,000. Bank of Montreal Can acquired a new stake in Intersect ENT during the 4th quarter valued at approximately $135,000. Campbell & CO Investment Adviser LLC acquired a new stake in Intersect ENT during the 3rd quarter valued at approximately $228,000. Finally, Simplex Trading LLC acquired a new stake in Intersect ENT during the 4th quarter valued at approximately $242,000. Hedge funds and other institutional investors own 84.49% of the company’s stock.
Shares of Intersect ENT Inc (XENT) opened at $37.75 on Monday. Intersect ENT Inc has a 1-year low of $14.60 and a 1-year high of $38.30.
A number of research analysts have commented on XENT shares. BidaskClub raised Intersect ENT from a “sell” rating to a “hold” rating in a report on Thursday, January 25th. JPMorgan Chase & Co. raised Intersect ENT from a “neutral” rating to an “overweight” rating in a report on Tuesday, January 2nd. Canaccord Genuity reaffirmed a “buy” rating and set a $36.00 target price on shares of Intersect ENT in a report on Monday, December 11th. Zacks Investment Research raised Intersect ENT from a “sell” rating to a “hold” rating in a report on Friday, January 26th. Finally, Guggenheim reaffirmed a “buy” rating on shares of Intersect ENT in a report on Thursday, March 1st. Five research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $33.38.
In other Intersect ENT news, CFO Jeryl L. Hilleman sold 12,835 shares of Intersect ENT stock in a transaction on Thursday, January 11th. The stock was sold at an average price of $33.81, for a total transaction of $433,951.35. Following the sale, the chief financial officer now owns 25,767 shares of the company’s stock, valued at approximately $871,182.27. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Gwen R. Carscadden sold 10,000 shares of Intersect ENT stock in a transaction on Friday, January 12th. The shares were sold at an average price of $34.35, for a total value of $343,500.00. Following the sale, the insider now directly owns 13,856 shares in the company, valued at approximately $475,953.60. The disclosure for this sale can be found here. In the last three months, insiders sold 136,310 shares of company stock worth $4,660,238. Company insiders own 13.70% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Intersect ENT Inc (XENT) Holdings Trimmed by Kopp Investment Advisors LLC” was reported by American Banking News and is the property of of American Banking News. If you are reading this story on another site, it was illegally copied and reposted in violation of US and international copyright & trademark laws. The correct version of this story can be accessed at https://www.americanbankingnews.com/2018/03/12/intersect-ent-inc-xent-holdings-trimmed-by-kopp-investment-advisors-llc.html.
Intersect ENT Profile
Intersect ENT, Inc is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care.
Receive News & Ratings for Intersect ENT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT and related companies with MarketBeat.com's FREE daily email newsletter.